PRC200-SS

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]

PRC200-SS

Identifiers
IUPAC name (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol
CAS Number	492434-58-9^Y
PubChem CID	20631904
ChemSpider	19318181^Y
ECHA InfoCard	100.207.294
Chemical and physical data
Formula	C20H21NO
Molar mass	291.394 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2
InChI InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1^N Key:RSZGIFQDUIROGN-WOJBJXKFSA-N^N
^NY (what is this?)  (verify)

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.

References

1. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–83. doi:10.1124/jpet.108.143610. PMID 18689611. S2CID 12635418.
2. "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
3. Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences. 120 (2): 269–83. doi:10.1093/toxsci/kfr013. PMID 21258088.